Invention Grant
US08808693B2 Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
有权
Semaphorin 3C（Sema3C）抑制剂治疗，方法和用途
- Patent Title: Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
- Patent Title (中): Semaphorin 3C（Sema3C）抑制剂治疗，方法和用途
-
Application No.: US13262196Application Date: 2010-04-01
-
Publication No.: US08808693B2Publication Date: 2014-08-19
- Inventor: Christopher J. Ong , Martin E. Gleave , Norihiro Hayashi , James Peacock
- Applicant: Christopher J. Ong , Martin E. Gleave , Norihiro Hayashi , James Peacock
- Applicant Address: CA Vancouver
- Assignee: The University of British Columbia
- Current Assignee: The University of British Columbia
- Current Assignee Address: CA Vancouver
- Agency: Bozicevic, Field & Francis LLP
- Agent Carol L. Francis
- International Application: PCT/CA2010/000514 WO 20100401
- International Announcement: WO2010/111792 WO 20101007
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00
Abstract:
Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule.
Public/Granted literature
- US20130028896A1 Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses Public/Granted day:2013-01-31
Information query
